文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌立体定向放疗后睾酮水平与性生活质量:多机构前瞻性试验分析

Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-05-17

结果显示睾酮在SBRT后短期出现一过性下降,至24个月恢复正常;激素域评分无显著变化,性功能域评分在19至24个月出现小效应量的临床可检测下降。

要点

  • SBRT后睾酮短暂下降,24个月时恢复至基线水平。
  • EPIC激素域评分下降未超过小效应量阈值。
  • EPIC性功能域评分在19至24个月出现小效应量下降。

核心结论

  • 前列腺癌SBRT后睾酮出现一过性下降并于24个月内恢复,激素域评分无显著变化,性功能域评分在19至24个月出现小效应量临床可检测下降。

研究设计与样本

  • 采用单侧t检验评估24个月内睾酮及EPIC问卷性功能和激素域评分变化。
  • EPIC评分变化与基于分布的临床最小重要差异阈值比较,以标准差的一半或三分之一分别定义中等或小效应量。

主要发现

  • 按基线睾酮三分位分组后,第一组患者睾酮倾向升高,第三组倾向降低。
  • EPIC激素域评分下降从未超过小效应量阈值;EPIC性功能域评分在19至24个月平均下降10.90分,超过小效应量阈值,但分组单独分析时该下降不存在。

关键数值与推荐

  • EPIC评分变化以大于各域标准差的一半或三分之一分别定义为中等或小效应量。
  • 睾酮变化百分比中位值与均值按3至6个月、7至12个月、13至18个月、19至24个月时间段分别报告。

临床怎么用

  • 在前列腺癌SBRT后随访中应关注睾酮水平的一过性下降,但至24个月多可恢复。
  • 性功能域评分在19至24个月可能出现小效应量的临床可检测下降,需结合分组情况个体化解读。

局限性

  • 性功能域评分下降在分组单独分析时不存在,提示整体结果可能受组间差异影响。
  • 未报告散射剂量与睾酮变化之间的直接剂量学关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The impact of higher scatter doses per fraction on testicular function and quality of life after prostate stereotactic body radiation therapy (SBRT) is poorly studied. METHODS AND MATERIALS: Six hundred thirty-six patients treated with SBRT for low- to intermediate-risk prostate cancer from 2009 to 2014 were included. Changes in testosterone and in sexual and hormonal domain scores on the Expanded Prostate Cancer Index Composite-26 (EPIC) questionnaire over a 24-month period were evaluated via a 1-sided t test. EPIC score changes were evaluated in comparison with a distribution-based minimal clinically important difference threshold, wherein changes of greater than one half or greater than one third of the standard deviation in each domain were considered as medium-sized or small-sized effects, respectively. RESULTS: Median and mean percent changes in testosterone at the 3- to 6-month, 7- to 12-month, 13- to 18-month, and 19- to 24-month time periods were -13.41% and -4.49% (P = .02); -12.23% and -2.77% (P = .13); -11.20% and -0.29% (P = .47); -5.00% and + 1.20% (P = .65). When analyzed after dividing the cohort into 3 groups based on baseline testosterone values using tertiles, testosterone tended to increase in patients in the first group and decrease in patients in the third group. Overall, the decline in EPIC hormonal domain scores never exceeded the threshold for a small-sized effect, though the decline in EPIC sexual domain scores did pass this threshold at the 19- to 24-month time period (mean 10.90 point decline). This decline was not present when groups were examined individually. CONCLUSIONS: In this large cohort of prospectively followed patients, there was a transient decline in testosterone shortly after SBRT that normalized by 24 months posttreatment. There was no significant change in EPIC hormonal domain scores. A significant decline in EPIC sexual domain scores, consistent with a small-sized clinically detectable difference, manifested between 19 and 24 months of follow-up. These results are consistent with testosterone decline patterns and sexual function changes seen after other forms of photon-based radiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yuan Y, Aghdam N, King CR, et al. Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. Int J Radiat Oncol Biol Phys. 2019. PMID: 31108142. doi:10.1016/j.ijrobp.2019.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。